*Refresh the page if the below document does not appear.
Advent International closes in on Suven Pharma buyout
Advent International has been on the top of the list to buy the Hyderabad-based Suven Pharmaceuticals, a listed contract research and manufacturing services (CRAMS) company. If the open offer is adopted completely, Advent may end up owning over 70% of the company.
Strides Pharma arm receives Rs 525-crore deferred consideration for Australian deal
Strides pharma shares price gained about 2% in the intraday trade on December 22 after the firm’s step-down subsidiary received deferred consideration for the sale of its Australian operations. The company stated that the proceeds will be used in deleveraging the balance sheet.
FDI in pharma counted approx ₹8,081 crores from April to September
The Central government on Thursday stated that Foreign Direct Investment (FDI) entry in the pharma sector (including both pharmaceuticals and medical devices) in the span of the current financial year from April to September has been ₹8,081 crores.
Kerala to cancel licenses of medical shops selling antibiotic drugs without prescription
Taking into account the fact that misuse of antibiotic drugs is responsible for the increasing cases of antibiotic resistance, the Kerala government has decided to cancel the licenses of the pharmacies that provide antibiotics without proper prescription.
USFDA gives approval to Alembic pharma for its Pregabalin capsules
Alembic Pharma has received Prior Approval Supplement (PAS) from the USFDA for its supplemental Abbreviated New Drug Application (sANDA) for Pregabalin capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg strengths.
Shilpa Medicare launches Capecitabine 1000 MG dispersible tablet for breast cancer
Karnataka-based Shilpa Medicare declared that they have launched Capecitabine 1000 MG dispersible tablet indicated for the treatment of breast cancer. It has novel technology for a faster dispersion within 90 seconds.
With global surge in COVID-19 cases, pharma industry’s supply chain may suffer
On Thursday, Prime Minister Narendra Modi
took review of the Covid-19 situation in India
by conducting a high level virtual meeting.
Apart from this, some industry experts stated
that even pharma industry will not be spared
and will take a hit if the current wave of Covid
lasts long.
